UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Annals of oncology, 2012-11, Vol.23 (11), p.2834-2842

2012

Volltextzugriff (PDF)

Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours

British journal of cancer, 2008-11, Vol.99 (9), p.1387-1394

2008

Volltextzugriff (PDF)

A Phase 3 Trial of Ganitumab with Gemcitabine as First-Line Treatment of Metastatic Pancreatic Cancer: A Safety Update from the Gamma Trial

Annals of oncology, 2012-10, Vol.23, p.xi15

2012

Volltextzugriff (PDF)

Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.S1-S1-4

2010

Volltextzugriff (PDF)

Safety and pharmacokinetics (PK) of AMG 706 in combination with gemcitabine for the treatment of patients (pts) with solid tumors

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.14005-14005

2007

Volltextzugriff (PDF)

Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.14057-14057

2007

Volltextzugriff (PDF)

Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4081-4081

2007

Volltextzugriff (PDF)

Initial results from ongoing phase I trials of a novel pan bcl-2 family small molecule inhibitor

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3180-3180

2005

Volltextzugriff (PDF)

A phase I and pharmacokinetic (PK) study of docetaxel (DOC) and oxaliplatin (OX)

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.2105-2105

2005

Volltextzugriff (PDF)

Pulse dose imatinib (Im) and weekly paclitaxel (P) phase I trial for advanced refractory solid tumors

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3118-3118

2005

Volltextzugriff (PDF)

Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.2503-2503

2005

Volltextzugriff (PDF)

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Annals of oncology, 2012-11, Vol.23 (11), p.2834

2012

Volltextzugriff (PDF)

On the origin of leakage currents in silicon-on-sapphire MOS transistors

IEEE transactions on electron devices, 1977-06, Vol.24 (6), p.730-738

McGreivy, D.J.

1977

Volltextzugriff (PDF)

Radiation-induced leakage currents in n-channel Silicon-on-sapphire MOST's

IEEE transactions on electron devices, 1977-11, Vol.24 (11), p.1277-1284

1977

Volltextzugriff (PDF)

The effect of arsenic in improving lifetime in silicon-on-sapphire films

Applied physics letters, 1974-01, Vol.25 (9), p.505-506

1974

Volltextzugriff (PDF)

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

The New England journal of medicine, 2016-01, Vol.374 (4), p.323-332

2016

Volltextzugriff (PDF)

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

The New England journal of medicine, 2013-08, Vol.369 (6), p.507-516

2013

Volltextzugriff (PDF)

A new high speed I/sup 2/L structure

IEEE journal of solid-state circuits, 1977-04, Vol.12 (2), p.114-118

1977

Volltextzugriff (PDF)

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

The New England journal of medicine, 2014-07, Vol.371 (3), p.213-223

2014

Volltextzugriff (PDF)

A new high speed IIL structure (Integrated Injection Logic)

IEEE journal of solid-state circuits, 1977-04, Vol.SC-12, p.114-118

1977

Volltextzugriff (PDF)

IIB-3 high speed I(2)L technology fabricated with double Schottky diodes and "Up-diffused" doping profile

IEEE transactions on electron devices, 1976-11, Vol.23 (11), p.1252-1252

1976

Volltextzugriff (PDF)

Data Augmentation for Neutron Spectrum Unfolding with Neural Networks

Journal of Nuclear Engineering, 2023-01, Vol.4 (1), p.77-95

2023

Volltextzugriff (PDF)

An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma (MCC) who have failed treatment with anti-PD-1/L1 immunotherapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS9602-TPS9602

2019

Volltextzugriff (PDF)

BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53 WT relapsed/refractory (R/R) myelofibrosis (MF)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS7057-TPS7057

2021

Volltextzugriff (PDF)

KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53 WT ) Merkel cell carcinoma (MCC) after anti–PD-1/L1 immunotherapy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10072-10072

2020

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(35)
Tagungsberichte
(1)

Sprache

Englisch
(36)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours

A Phase 3 Trial of Ganitumab with Gemcitabine as First-Line Treatment of Metastatic Pancreatic Cancer: A Safety Update from the Gamma Trial

Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)

Safety and pharmacokinetics (PK) of AMG 706 in combination with gemcitabine for the treatment of patients (pts) with solid tumors

Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer

Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)

Initial results from ongoing phase I trials of a novel pan bcl-2 family small molecule inhibitor

A phase I and pharmacokinetic (PK) study of docetaxel (DOC) and oxaliplatin (OX)

Pulse dose imatinib (Im) and weekly paclitaxel (P) phase I trial for advanced refractory solid tumors

Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

On the origin of leakage currents in silicon-on-sapphire MOS transistors

Radiation-induced leakage currents in n-channel Silicon-on-sapphire MOST's

The effect of arsenic in improving lifetime in silicon-on-sapphire films

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

A new high speed I/sup 2/L structure

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

A new high speed IIL structure (Integrated Injection Logic)

IIB-3 high speed I(2)L technology fabricated with double Schottky diodes and "Up-diffused" doping profile

Data Augmentation for Neutron Spectrum Unfolding with Neural Networks

An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma (MCC) who have failed treatment with anti-PD-1/L1 immunotherapy

BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53 WT relapsed/refractory (R/R) myelofibrosis (MF)

KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53 WT ) Merkel cell carcinoma (MCC) after anti–PD-1/L1 immunotherapy

Suchergebnisse filtern